Merck KGaA’s Phase 3 trials of xevinapant, the cancer drug it licensed from Debiopharm in 2021, are winding down after the drug showed that it …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Johnson & Johnson touted “significant progress” in manufacturing Carvykti, the CAR-T therapy it developed with Legend Biotech, after having to find ways to improve production
Continuous rhythm monitoring showed the timeline in which heart rate and atrial tachycardias typically arise after binge drinking by young adults, researchers reported. In people
The psychedelic ibogaine is unlikely to ever receive approval as a treatment for opioid addiction, the federal government’s top addiction researcher said Thursday. The remarks